When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
DCPH - Deciphera: Analysis Of The Market Potential Of Ripretinib
Deciphera Pharmaceuticals Inc.
Ripretinib is Deciphera's (DCPH) lead drug candidate and it is being tested in GIST, or gastrointestinal stromal tumors. Recently, the drug fared positively in a phase 3 trial called INVICTUS evaluating ripretinib in patients with fourth-line and fourth-line plus GIST.
Given those results, it is becoming important to be able to put a number to the drug's market potential, and the company's eventual valuation.
However, it is something of a problem to determine ripretinib's market potential because, as we said in our previous article, it isn't just GIST that the drug is targeting.